Physician profile
Fernando A Cobos
NPI 1356383947
$1,269.50
in general payments reported to CMS, 2019-2025
11 companies · $93.18 in 2025
The $93.18 reported for 2025 was less than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.89 · 2021: $302 · 2022: $269 · 2023: $441 · 2024: $134 · 2025: $93.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.27 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $240.39 | 2021-2024 | Aristada, Vivitrol, Lybalvi |
| Lundbeck LLC | $235.72 | 2021-2024 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $184.61 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $175.11 | 2019-2024 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $103.23 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $92.49 | 2023 | Auvelity |
| Abbvie INC. | $86.84 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $66.48 | 2021-2023 | Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.93 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $32.85 | 2021-2023 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Cobos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.